Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) FCF Margin (2016 - 2025)

Historic FCF Margin for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 20.87%.

  • Amicus Therapeutics' FCF Margin rose 373500.0% to 20.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.62%, marking a year-over-year increase of 80000.0%. This contributed to the annual value of 7.09% for FY2024, which is 120800.0% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' FCF Margin is 20.87%, which was up 373500.0% from 18.7% recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' FCF Margin ranged from a high of 20.87% in Q3 2025 and a low of 110.27% during Q1 2021
  • Its 5-year average for FCF Margin is 30.65%, with a median of 20.09% in 2022.
  • Its FCF Margin has fluctuated over the past 5 years, first soared by 962300bps in 2023, then crashed by -357500bps in 2025.
  • Amicus Therapeutics' FCF Margin (Quarter) stood at 87.97% in 2021, then dropped by -8bps to 94.73% in 2022, then surged by 102bps to 1.5% in 2023, then crashed by -287bps to 2.81% in 2024, then surged by 843bps to 20.87% in 2025.
  • Its last three reported values are 20.87% in Q3 2025, 18.7% for Q2 2025, and 6.02% during Q1 2025.